Given that anti-angiogenic therapies have shown promise in thyroid cancer, combined inhibition of Src and MEK1/2 may be an especially promising therapy by targeting both the tumor and microenvironment [47,48]. This evidence concerns the gene MAP2K1 and neoplasm.